TD Cowen analyst Phil Nadeau raised the price target on Biogen (NASDAQ: BIIB) to $250.00 (from $225.00) while maintaining a Buy rating.

The analyst comments "We are issuing an updated BIIB model ahead of Q3:26 earnings. We have revised our model to be consistent with BIIB's guidance for Q3:26 and Q4:26 IPR&D. Our Q3:26 and 2026 non-GAAP EPS estimates have changed from $1.90 and $12.40 to $1.99 and $12.30, respectively. Our P.T. has increased from $225 to $250. Please see TD Cowen's Q3 Biotech Earnings Preview for a discussion. Remain Buy."